Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bringing vaccinology to the world.
Gerke C, Phalipon A, Tangy F. Gerke C, et al. Hum Vaccin Immunother. 2018;14(9):2105-2106. doi: 10.1080/21645515.2018.1490379. Epub 2018 Jul 26. Hum Vaccin Immunother. 2018. PMID: 30047812 Free PMC article. No abstract available.
Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study.
Launay O, Artaud C, Lachâtre M, Ait-Ahmed M, Klein J, Luong Nguyen LB, Durier C, Jansen B, Tomberger Y, Jolly N, Grossmann A, Tabbal H, Brunet J, Gransagne M, Choucha Z, Batalie D, Delgado A, Müllner M, Tschismarov R, Berghmans PJ, Martin A, Ramsauer K, Escriou N, Gerke C. Launay O, et al. Among authors: gerke c. EBioMedicine. 2022 Jan;75:103810. doi: 10.1016/j.ebiom.2021.103810. Epub 2022 Jan 16. EBioMedicine. 2022. PMID: 35045362 Free PMC article. Clinical Trial.
An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.
Vesin B, Lopez J, Noirat A, Authié P, Fert I, Le Chevalier F, Moncoq F, Nemirov K, Blanc C, Planchais C, Mouquet H, Guinet F, Hardy D, Vives FL, Gerke C, Anna F, Bourgine M, Majlessi L, Charneau P. Vesin B, et al. Among authors: gerke c. Mol Ther. 2022 Sep 7;30(9):2984-2997. doi: 10.1016/j.ymthe.2022.04.016. Epub 2022 Apr 27. Mol Ther. 2022. PMID: 35484842 Free PMC article.
A Modified mRNA Vaccine Targeting Immunodominant NS Epitopes Protects Against Dengue Virus Infection in HLA Class I Transgenic Mice.
Roth C, Cantaert T, Colas C, Prot M, Casadémont I, Levillayer L, Thalmensi J, Langlade-Demoyen P, Gerke C, Bahl K, Ciaramella G, Simon-Loriere E, Sakuntabhai A. Roth C, et al. Among authors: gerke c. Front Immunol. 2019 Jun 21;10:1424. doi: 10.3389/fimmu.2019.01424. eCollection 2019. Front Immunol. 2019. PMID: 31293584 Free PMC article.
COVID-19 vaccination, time for a second breath?
Gerke CE, Pulverer B, Sansonetti PJ. Gerke CE, et al. EMBO Mol Med. 2022 Mar 7;14(3):e15810. doi: 10.15252/emmm.202215810. Epub 2022 Feb 25. EMBO Mol Med. 2022. PMID: 35212155 Free PMC article.
Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe.
Launay O, Lewis DJM, Anemona A, Loulergue P, Leahy J, Sciré AS, Maugard A, Marchetti E, Zancan S, Huo Z, Rondini S, Marhaba R, Finco O, Martin LB, Auerbach J, Cohen D, Saul A, Gerke C, Podda A. Launay O, et al. Among authors: gerke c. EBioMedicine. 2017 Aug;22:164-172. doi: 10.1016/j.ebiom.2017.07.013. Epub 2017 Jul 15. EBioMedicine. 2017. PMID: 28735965 Free PMC article. Clinical Trial.
Draft genomes of Shigella strains used by the STOPENTERICS consortium.
Rossi O, Baker KS, Phalipon A, Weill FX, Citiulo F, Sansonetti P, Gerke C, Thomson NR. Rossi O, et al. Among authors: gerke c. Gut Pathog. 2015 Jun 4;7:14. doi: 10.1186/s13099-015-0061-5. eCollection 2015. Gut Pathog. 2015. PMID: 26042182 Free PMC article.
65 results